Skip to main content
rounds.

Evidence digest

Neuro-Ophthalmology: the evidence, summarized every weekday

Peer-reviewed papers and clearly-labeled preprints in neuro-ophthalmology, summarized and ranked by evidence level. Top studies from PubMed and ClinicalTrials.gov. Updated every weekday at 06:00 CET. Built by physicians, for physicians.

Subscribe · €49/year →See the methodology →

What rounds. covers in neuro-ophthalmology

  • Optic neuritis & MS/NMO
  • Ischemic optic neuropathies (NAION/GCA)
  • Pituitary & chiasmal lesions
  • Diplopia & ocular motor palsies
  • Idiopathic intracranial hypertension
  • Nystagmus

Landmark papers · neuro-ophthalmology

Hand-picked by the editorial team. These are the studies that shaped current practice in neuro-ophthalmology.

  1. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

    JAMA · Wall M. et al. · Wednesday, January 1, 2014

  2. L2 · prospective cohort

    A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis

    The New England Journal of Medicine · Beck Roy W. et al. · Wednesday, January 1, 1992

  3. L2 · prospective cohort

    Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

    The New England journal of medicine · Pittock S. et al. · Tuesday, January 1, 2019

  4. L2 · prospective cohort

    Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

    Lancet · Cree B. et al. · Tuesday, January 1, 2019

How papers reach the neuro-ophthalmology brief

  1. Source. Every paper is fetched directly from PubMed and ClinicalTrials.gov. No paywalled aggregators. No editorial press releases.
  2. Grading. Each paper is assigned an evidence level from L1 (RCT or meta-analysis) to L5 (editorial). Bias risk is flagged separately. Both labels are visible on every card.
  3. Summarization. A nine-gate validator stack checks every summary for source faithfulness, numeric accuracy, drug-safety language, unsupported claims, and clinical-decision overreach. Anything that fails a gate is blocked, not silently weakened.
  4. Delivery. Ten papers. Twelve minutes. Every weekday at 06:00 CET. Subscribers can rate any paper as off-topic and it drops out of their feed.

The full pipeline, validators, and the founder's editorial overrides are documented on the methodology page.

Frequently asked

How do I keep up with new neuro-ophthalmology research?
rounds. reads the new neuro-ophthalmology literature from PubMed and ClinicalTrials.gov every weekday, grades each paper on the CEBM evidence hierarchy, and delivers the few that change practice as a twelve-minute morning brief. Every number in a summary is checked against the source paper.
What are the landmark neuro-ophthalmology trials?
The studies that shaped current neuro-ophthalmology practice are listed above under “Landmark papers”, each linked to a structured summary with its evidence level, effect size, and bias signals.
Is rounds. free?
A card is required to start your 14-day trial: full access to the whole brief and the Read on every paper, 10 papers every weekday on the web and in your inbox at 06:00 CET. After that, Pro (€49/year) is billed automatically unless you cancel. Cancel anytime.

Other subspecialties